CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 41 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
University of Arkansas for Medical Sciences (UAMS)
Little Rock, AR
- Accepting patients
- Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Accepting patients
Stanford University Cancer Institute (Palo Alto)
Stanford, CA
- Accepting patients
- Accepting patients
- Accepting patients
Holden Comprehensive Cancer Center - University of Iowa
University of Iowa Hospitals and Clinics
Iowa City, IA
- Accepting patients
University of Maryland Medical Center
Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, MD
- Accepting patients
Boston Medical Center
Boston, MA
- Accepting patients
1,341 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.